{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:07:54Z","timestamp":1789168074591,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93021C00012"],"award-info":[{"award-number":["75N93021C00012"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37AI054165"],"award-info":[{"award-number":["R37AI054165"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","award":["75A50122C00008"],"award-info":[{"award-number":["75A50122C00008"]}],"id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","award":["75N93021D00021"],"award-info":[{"award-number":["75N93021D00021"]}],"id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["75N93021C00014 \\u2013 option 12A"],"award-info":[{"award-number":["75N93021C00014 \\u2013 option 12A"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N91022F00007"],"award-info":[{"award-number":["75N91022F00007"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.vaccine.2026.128348","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T23:37:12Z","timestamp":1771198632000},"page":"128348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances"],"prefix":"10.1016","volume":"76","author":[{"given":"Fei","family":"Heng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Magaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine G.","family":"Rouphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela R.","family":"Branche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Diemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann R.","family":"Falsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Graciaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kamidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica C.","family":"Kottkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne F.","family":"Luetkemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly C.","family":"Immergluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Presti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"B\u00e4cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Winokur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham M.","family":"Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahlene N.","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Atmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Posavad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjian","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat","family":"Makowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamodikoe K.","family":"Makhene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema U.","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm","family":"van Bakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128348_bb0005","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/14760584.2023.2232851","article-title":"Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early omicron era","volume":"22","author":"Pather","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2026.128348_bb0010","series-title":"Coronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4\/5 Component for COVID-19 Vaccine Booster Doses","author":"US Food and Drug Administration","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128348_bb0015","series-title":"Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023","author":"US Food and Drug Administration","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128348_bb0020","article-title":"SARS-CoV-2 omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines","volume":"14","author":"Pather","year":"2023","journal-title":"Front Immunol."},{"key":"10.1016\/j.vaccine.2026.128348_bb0025","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.15585\/mmwr.mm7148e1","article-title":"Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection - increasing community access to testing program, United States, September-November 2022","volume":"71","author":"Link-Gelles","year":"2022","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"10.1016\/j.vaccine.2026.128348_bb0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.32760","article-title":"Estimated effectiveness of COVID-19 vaccines against omicron or Delta symptomatic infection and severe outcomes","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.vaccine.2026.128348_bb0040","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0045","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0222-2024","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024","volume":"34","author":"Zhou","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.vaccine.2026.128348_bb0050","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2167410","article-title":"Effectiveness of the pre-omicron COVID-19 vaccines against omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: a systematic review","volume":"19","author":"Paul","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.vaccine.2026.128348_bb0055","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128348_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-042921-020956","article-title":"COVID-19: challenges of viral variants","volume":"74","author":"Jacobs","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0065","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0070","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning immunity after the BNT162b2 vaccine in Israel","volume":"385","author":"Goldberg","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0075","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMc2210093","article-title":"Effectiveness and durability of the BNT162b2 vaccine against omicron sublineages in South Africa","volume":"387","author":"Collie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2023.2143347","article-title":"Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic","volume":"22","author":"Solante","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2026.128348_bb0085","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa2200797","article-title":"Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar","volume":"386","author":"Abu-Raddad","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0090","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jamainternmed.2021.7382","article-title":"Odds of testing positive for SARS-CoV-2 following receipt of 3 vs 2 doses of the BNT162b2 mRNA vaccine","volume":"182","author":"Patalon","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0095","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against Covid-19 in Israel","volume":"385","author":"Bar-On","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.2022.17876","article-title":"Association of Primary and Booster Vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes","volume":"328","author":"Lin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128348_bb0105","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1056\/NEJMc2302462","article-title":"Durability of bivalent boosters against omicron subvariants","volume":"388","author":"Lin","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S2213-2600(23)00015-2","article-title":"Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022","volume":"11","author":"Wu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0115","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1038\/s41591-023-02503-4","article-title":"Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial","volume":"29","author":"Branche","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0120","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/cid\/ciad209","article-title":"Immunogenicity of the BA.1 and BA.4\/BA.5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized clinical trial","volume":"77","author":"Branche","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128348_bb0125","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128348_bb0130","series-title":"Vaccines","first-page":"35","article-title":"Correlates of Protection","author":"Plotkin","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128348_bb0135","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMp2211314","article-title":"A Covid-19 milestone attained \u2014 a correlate of protection for vaccines","volume":"387","author":"Gilbert","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0140","series-title":"Immunobridging to Evaluate Vaccines. US Food and Drug Administration","author":"Fink","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128348_bb0145","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0150","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0155","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0160","series-title":"WHO Technical Report Series, No. 1004, Annex 9. Guidelines on clinical evaluation of vaccines: regulatory expectations","author":"WHO Expert Committee on Biological Standardization","year":"2017"},{"key":"10.1016\/j.vaccine.2026.128348_bb0165","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/cid\/ciae465","article-title":"Neutralizing antibody immune correlates for a recombinant protein vaccine in the COVAIL trial","volume":"80","author":"Fong","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128348_bb0170","article-title":"Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128348_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009406","article-title":"Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection","volume":"17","author":"Rolland","year":"2021","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.vaccine.2026.128348_bb0180","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-46536-w","article-title":"Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on spike sequence features","volume":"15","author":"Magaret","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128348_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/sim.10345","article-title":"Estimation and hypothesis testing of strain-specific vaccine efficacy with missing strain types with application to a COVID-19 vaccine trial","volume":"44","author":"Heng","year":"2025","journal-title":"Stat. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1714250115","article-title":"Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials","volume":"115","author":"Juraska","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128348_bb0195","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2308942121","article-title":"Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features","volume":"121","author":"Juraska","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.vaccine.2026.128348_bb0200","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature11519","article-title":"Increased HIV-1 vaccine efficacy against viruses with genetic signatures in env V2","volume":"490","author":"Rolland","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128348_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185959","article-title":"Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of env-gp120","volume":"12","author":"deCamp","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128348_bb0210","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/bimj.201700002","article-title":"Hypothesis tests for stratified mark-specific proportional hazards models with missing covariates, with application to HIV vaccine efficacy trials","volume":"60","author":"Sun","year":"2018","journal-title":"Biom. J."},{"key":"10.1016\/j.vaccine.2026.128348_bb0215","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1016\/j.vaccine.2022.08.055","article-title":"Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia","volume":"40","author":"Qi","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128348_bb0220","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41586-024-07636-1","article-title":"Spike deep mutational scanning helps predict success of SARS-CoV-2 clades","volume":"631","author":"Dadonaite","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128348_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38867-x","article-title":"Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants","volume":"14","author":"Gonzalez-Reiche","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.vaccine.2026.128348_bb0230","series-title":"vRAPID: Virus Reference-Based Assembly Pipeline and Identification","author":"Khalil","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128348_bb0235","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1093\/bioinformatics\/bty407","article-title":"Nextstrain: real-time tracking of pathogen evolution","volume":"34","author":"Hadfield","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.vaccine.2026.128348_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/veab064","article-title":"Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool","volume":"7","author":"O\u2019Toole","year":"2021","journal-title":"Virus Evol"},{"key":"10.1016\/j.vaccine.2026.128348_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.012","article-title":"Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding","volume":"182","author":"Starr","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128348_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2024.06.015","article-title":"Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin","volume":"32","author":"Welsh","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2026.128348_bb0255","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/rssc.12417","article-title":"A hybrid approach for the stratified mark-specific proportional hazards model with missing covariates and missing Marks, with application to vaccine efficacy trials","volume":"69","author":"Sun","year":"2020","journal-title":"J. R. Stat. Soc.: Ser. C: Appl. Stat."},{"key":"10.1016\/j.vaccine.2026.128348_bb0260","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41591-022-01877-1","article-title":"Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance","volume":"28","author":"Cao","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.vaccine.2026.128348_bb0265","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.13091","article-title":"Correlates of protection against SARS-CoV-2 infection and COVID-19 disease","volume":"310","author":"Goldblatt","year":"2022","journal-title":"Immunol. Rev."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:48:30Z","timestamp":1778737710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"alternative-id":["S0264410X26001568"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128348","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128348"}}